A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapywith Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage Iand II Classic Hodgkin Lymphoma
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAU7216
U.S. Govt. ID: NCT05675410
Contact: Nobuko Hijiya, MD: 2123059770 / nh2636@cumc.columbia.edu
Additional Study Information: This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60 years with newly diagnosed early-stage cHL and will investigate the targeted CD30-antibody drug conjugate, Brentuximab Vedotin (Bv), with PD-1 blockade (nivolumab) compared with a standard chemotherapy regimen, with or without radiotherapy.
Investigator
Nobuko Hijiya, MD
Do You Qualify?
Are you between 5 and 60 years old? Yes No
Do you have newly diagnosed, untreated, histologically confirmed classic Hodgkin lymphoma (cHL) with Stage I or II disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Nobuko Hijiya, MD
nh2636@cumc.columbia.edu
2123059770
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE